Last reviewed · How we verify
IBD98-M:
At a glance
| Generic name | IBD98-M: |
|---|---|
| Also known as | Mesalamine-Sodium Hyaluronic 400 mg-57.5 mg |
| Sponsor | Holy Stone Healthcare Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M (PHASE2)
- Pharmacokinetics of IBD98-M 400mg-57.5/Day in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBD98-M: CI brief — competitive landscape report
- IBD98-M: updates RSS · CI watch RSS
- Holy Stone Healthcare Co., Ltd portfolio CI